Novartis AG ADR Stock
€122.00
Your prediction
Novartis AG ADR Stock
Pros and Cons of Novartis AG ADR in the next few years
Pros
Cons
Performance of Novartis AG ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novartis AG ADR | 0.410% | 2.954% | 7.965% | 25.514% | 2.954% | 45.585% | 58.442% |
| Roche Holding AG ADR | 0.820% | 4.100% | 9.254% | 28.639% | 4.431% | 24.707% | 31.226% |
| Bayer AG ADR | 5.820% | 3.627% | 8.696% | 100.803% | 13.636% | -20.000% | -23.077% |
| Astrazeneca ADR | 0.620% | 3.822% | 3.822% | 23.485% | 3.165% | 23.112% | 95.913% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon reviewing the financial statements of Novartis (NASDAQ: NVS), a prominent player in the pharmaceutical industry, the general impression suggests that the company maintains a solid financial standing. With substantial total assets, a strong revenue base, and a broad diversification through various investments, Novartis appears to be a robust organization in terms of financial health.
Cash Position: Novartis has maintained a considerable cash position in recent years, end of 2022 standing at $7.52B. A strong liquidity profile allows the company to invest in research and development or pursue mergers and acquisitions to drive future growth.
Increasing Revenue: The total revenue increased from $49.9B in 2020 to $52.9B in 2021 and further up to $58.2B in 2022. This growth suggests that the company is effectively generating business, increasing market share, and expanding its product portfolio.
Comments
News
New Investors: 3 Stocks to Build Your Portfolio Around in 2026
If you're looking to get started with investing, there are many solid stocks you can put in your portfolio. Ideally, you'll want to start with some blue chip stocks to be pillars that you can hang
Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill
Novo Nordisk (NYSE:NVO), which develops and markets diabetes and obesity treatments, closed Tuesday’s session at $51.61, up 7.30% after U.S. approval of its once-daily oral Wegovy weight-loss pill
Why Novartis Stock Topped the Market Today
Although it's never guaranteed that regulatory approval of a new drug will juice the share price of its developer, this often happens in the pharmaceutical field. Sure enough, after receiving